Most Americans would prefer brand-name drugs—but end up buying generic versions because of the cost, new consumer research ...

From soaring drug expenses in the Great Plains to rising supply costs in the West, regional disparities highlight the unique pressures facing hospital leaders. As labor shortages persist, supply ...

Recently, a letter to the editor I wrote was published in the Arkansas Democrat-Gazette on the subject of skyrocketing health-care costs, inclusive of rising pharmaceutical drug prices. I referenced ...

Polypharmacy, biosimilars, and GLP-1s among the evolving trends likely to play out in the pharmacy benefits space.

Kim Gillan writes, As the 119th Congress gets to work, I’m hopeful that Montana’s Congressional Delegation will prioritize and support legislation that addresses the ever-growing cost of prescription ...

CVS CEO David Joyner’s comments come as lawmakers on both sides of the aisle and President Donald Trump have signaled ...

CVS Health’s adjusted fourth-quarter profit handily beat Wall Street’s estimates, even as the drugstore chain and pharmacy ...

Prices for brand-name drugs in the U.S. are three times what the same drugs cost in other countries. And in a recent KFF survey, 3 in 10 adults reported not taking their medicine as prescribed at some ...

Payouts to shareholders of large publicly traded health companies more than tripled over the past two decades, new research ...

According to AAHC, the new fee would result in an estimated annual increase of $900 per person or $3,600 per family in ...

Learn about the financial strain caused by the skyrocketing demand and costs of GLP-1 drugs, and how health plans and providers are struggling to balance it.

Across healthcare system, stakeholders share blame for high costs. This includes hospitals, drugmakers, insurers and others ...